Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for ...

The European Medicines Agency has begun a review of medicines to treat alcohol dependency that contain sodium oxybate, it ...

Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a ...

Enrollment in company’s first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

The National Health Technology Assessment System (SiNATS) has contributed over the last decade to improving access to medicines, promoting the sustainability of the SNS and reducing waste, but ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

A new gene therapy delivery device could let hospital pharmacies make personalized nanomedicines to order. This democratized ...

First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025; Marks the ...

The marketing authorisation application (MAA) for Nidlegy was submitted in June 2024, but Philogen decided to withdraw it due ...

Siena: Sun Pharma European partner Philogen S.p.A has voluntarily withdrawn the application for marketing authorization to ...